Glimepiride Accord Healthcare

Glimepiride Accord Healthcare is an oral prescription medication that contains the active ingredient glimepiride. Marketed in the European Union as a generic sulfonylurea, it is used to treat type 2 diabetes mellitus. The product is supplied as tablets (strength not specified) and works by stimulating insulin release from pancreatic beta cells, helping lower elevated blood glucose levels under medical supervision and may be combined with lifestyle measures.

Glimepiride Accord Healthcare is indicated for the oral management of hyperglycemia in adults with type 2 diabetes mellitus, typically when diet and exercise alone are insufficient.

- Used as monotherapy in patients with newly diagnosed type 2 diabetes who do not achieve glycemic targets with non‑pharmacologic measures. - Added to other oral antidiabetic agents (e.g., metformin) when combination therapy is required. - Considered when a rapid reduction in fasting plasma glucose is desired. - Prescribed for patients with preserved pancreatic beta‑cell function. - Utilized as part of an individualized diabetes care plan under physician supervision.

Glimepiride Accord Healthcare may cause a range of adverse effects; they are categorized by frequency and clinical significance.

Common: - Mild hypoglycemia (especially if meals are missed) - Nausea or abdominal discomfort - Headache - Dizziness

Serious: - Severe hypoglycemia leading to loss of consciousness - Allergic reactions such as rash, itching, or swelling - Hematologic abnormalities (e.g., leukopenia, thrombocytopenia)

Before initiating glimepiride therapy, clinicians should evaluate several patient-specific factors and monitor for potential risks.

- Assess renal and hepatic function; dose adjustment may be required in impairment. - Verify that the patient has adequate pancreatic beta‑cell reserve. - Use caution in elderly patients due to increased hypoglycemia risk. - Avoid use during pregnancy; safety data are insufficient. - Counsel patients on recognizing and managing hypoglycemia. - Review concomitant medications that may potentiate glucose‑lowering effects.

Glimepiride can interact with other drugs, altering its glucose‑lowering action or increasing adverse event risk.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glimepiride plasma levels. - Discontinuous alcohol intake, which can potentiate hypoglycemic episodes.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can affect glucose tolerance.